Compugen (CGEN) Stock: Why It's Up Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $1.97, +0.51% vs the prior close of $1.96.
- Volume 159.25K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CGEN rises 0.5% to $1.97. Closed at $1.97, +0.51% vs the prior close of $1.96. Day range $1.95–$2.00, opened at $1.97.
CGEN daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — CGEN rises 0.5% to $1.97
- Closed at $1.97, +0.51% vs the prior close of $1.96. Day range $1.95–$2.00, opened at $1.97.
- Volume was 159.25K shares, 0.7x its 50-day average of 241.11K.
- Price is -17.9% vs its 50-day average ($2.40) and -13.8% vs its 200-day average ($2.29).
- 52-week range $1.43–$3.24; today's close sits at 30% of that range, 39.2% below the 52-week high.
Oct 16, 2026 — CGEN slides 5.8% to $1.96, a 3-month low
- Closed at $1.96, -5.77% vs the prior close of $2.08. Day range $1.93–$2.09, opened at $2.08.
- Volume was 169.43K shares, 0.7x its 50-day average of 241.86K.
- Price is -18.7% vs its 50-day average ($2.41) and -14.2% vs its 200-day average ($2.28).
- 52-week range $1.43–$3.24; today's close sits at 29% of that range, 39.5% below the 52-week high.
Oct 15, 2026 — CGEN jumps 4.0% to $2.08
- Closed at $2.08, +4.00% vs the prior close of $2.00. Day range $2.02–$2.13, opened at $2.02.
- Volume was 200.10K shares, 0.8x its 50-day average of 242.64K.
- Price is -13.9% vs its 50-day average ($2.42) and -8.8% vs its 200-day average ($2.28).
- 52-week range $1.43–$3.24; today's close sits at 36% of that range, 35.8% below the 52-week high.
Oct 14, 2026 — CGEN rises 1.0% to $2.00
- Closed at $2.00, +1.01% vs the prior close of $1.98. Day range $1.95–$2.02, opened at $2.01.
- Volume was 378.10K shares, 1.6x its 50-day average of 241.98K.
- Price is -17.4% vs its 50-day average ($2.42) and -12.2% vs its 200-day average ($2.28).
- 52-week range $1.43–$3.24; today's close sits at 31% of that range, 38.3% below the 52-week high.
Oct 13, 2026 — CGEN slides 4.3% to $1.98, a 3-month low
- Closed at $1.98, -4.35% vs the prior close of $2.07. Day range $1.96–$2.09, opened at $2.09.
- Volume was 223.40K shares, 0.9x its 50-day average of 249.37K.
- Price is -18.4% vs its 50-day average ($2.43) and -13.0% vs its 200-day average ($2.28).
- 52-week range $1.43–$3.24; today's close sits at 30% of that range, 38.9% below the 52-week high.
Oct 12, 2026 — CGEN dips 2.8% to $2.07, a 3-month low
- Closed at $2.07, -2.82% vs the prior close of $2.13. Day range $2.07–$2.13, opened at $2.13.
- Volume was 86.50K shares, 0.3x its 50-day average of 254.65K — lighter than usual.
- Price is -15.0% vs its 50-day average ($2.44) and -8.9% vs its 200-day average ($2.27).
- 52-week range $1.43–$3.24; today's close sits at 35% of that range, 36.1% below the 52-week high.
Oct 9, 2026 — CGEN rises 0.5% to $2.13
- Closed at $2.13, +0.47% vs the prior close of $2.12. Day range $2.08–$2.13, opened at $2.13.
- Volume was 123.40K shares, 0.5x its 50-day average of 255.47K — lighter than usual.
- Price is -12.8% vs its 50-day average ($2.44) and -6.2% vs its 200-day average ($2.27).
- 52-week range $1.43–$3.24; today's close sits at 39% of that range, 34.3% below the 52-week high.
Oct 8, 2026 — CGEN dips 1.4% to $2.12, a 3-month low, 6 down days in a row
- Closed at $2.12, -1.40% vs the prior close of $2.15. Day range $2.04–$2.16, opened at $2.14.
- Volume was 243.20K shares, 1.0x its 50-day average of 254.58K.
- Price is -13.3% vs its 50-day average ($2.45) and -6.5% vs its 200-day average ($2.27).
- 52-week range $1.43–$3.24; today's close sits at 38% of that range, 34.6% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — CGEN slides 3.2% to $2.15, a 3-month low, 5 down days in a row
- Closed at $2.15, -3.15% vs the prior close of $2.22. Day range $2.13–$2.23, opened at $2.22.
- Volume was 201.80K shares, 0.8x its 50-day average of 254.12K.
- Price is -12.2% vs its 50-day average ($2.45) and -5.1% vs its 200-day average ($2.26).
- 52-week range $1.43–$3.24; today's close sits at 40% of that range, 33.6% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — CGEN slides 3.9% to $2.22, a 3-month low, 4 down days in a row
- Closed at $2.22, -3.90% vs the prior close of $2.31. Day range $2.21–$2.33, opened at $2.32.
- Volume was 264.90K shares, 1.1x its 50-day average of 250.89K.
- Price is -9.4% vs its 50-day average ($2.45) and -1.8% vs its 200-day average ($2.26).
- 52-week range $1.43–$3.24; today's close sits at 44% of that range, 31.5% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — CGEN ends flat (+0.0%) to $2.31, 3 down days in a row
- Closed at $2.31, +0.00% vs the prior close of $2.31. Day range $2.25–$2.32, opened at $2.30.
- Volume was 198.80K shares, 0.8x its 50-day average of 250.92K.
- Price is -5.8% vs its 50-day average ($2.45) and +2.3% vs its 200-day average ($2.26).
- 52-week range $1.43–$3.24; today's close sits at 49% of that range, 28.7% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — CGEN dips 1.3% to $2.31, a 1-month low
- Closed at $2.31, -1.28% vs the prior close of $2.34. Day range $2.31–$2.38, opened at $2.34.
- Volume was 113.90K shares, 0.5x its 50-day average of 252.13K — lighter than usual.
- Price is -5.8% vs its 50-day average ($2.45) and +2.5% vs its 200-day average ($2.25).
- 52-week range $1.43–$3.24; today's close sits at 49% of that range, 28.7% below the 52-week high.
CGEN bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Price is -17.9% vs its 50-day average — short-term trend is down.
- Price is -13.8% vs its 200-day average — below the long-term trend line.
- Insider selling outweighs buying: 25 sales vs 0 open-market buys among the 25 most recent reported insider trades (Form 4, last 12 months).
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
CGEN latest news & SEC filings
Every SEC filing by or about CGEN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 10, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 4, 2026 · Form UPLOAD — SEC staff letter to the company
SEC staff letter to the company
Aug 3, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 3, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 28, 2026 · Form CORRESP — Company letter to the SEC
Company letter to the SEC
Jul 17, 2026 · Form UPLOAD — SEC staff letter to the company
SEC staff letter to the company
Things to know before you trade CGEN
- How much it moves: over the last 20 sessions the average daily move was 2.22% (largest 6.0%).
- Liquidity: about 178.69K shares (≈$352.01K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.97 vs a range of $1.43–$3.24 (30% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Zurit Levine sold 1,875 shares on Jul 9, 2026.
- Latest filings: 6-K Sep 10, 2026; 6-K Aug 3, 2026; 6-K Aug 3, 2026.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CGEN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 1.97 | 2.00 | 1.95 | 1.97 | 159.25K |
| Oct 16, 2026 | 2.08 | 2.09 | 1.93 | 1.96 | 169.40K |
| Oct 15, 2026 | 2.02 | 2.13 | 2.02 | 2.08 | 200.10K |
| Oct 14, 2026 | 2.01 | 2.02 | 1.95 | 2.00 | 378.10K |
| Oct 13, 2026 | 2.09 | 2.09 | 1.96 | 1.98 | 223.40K |
| Oct 12, 2026 | 2.13 | 2.13 | 2.07 | 2.07 | 86.50K |
| Oct 9, 2026 | 2.13 | 2.13 | 2.08 | 2.13 | 123.40K |
| Oct 8, 2026 | 2.14 | 2.16 | 2.04 | 2.12 | 243.20K |
| Oct 7, 2026 | 2.22 | 2.23 | 2.13 | 2.15 | 201.80K |
| Oct 6, 2026 | 2.32 | 2.33 | 2.21 | 2.22 | 264.90K |
| Oct 5, 2026 | 2.30 | 2.32 | 2.25 | 2.31 | 198.80K |
| Oct 2, 2026 | 2.34 | 2.38 | 2.31 | 2.31 | 113.90K |
| Oct 1, 2026 | 2.39 | 2.44 | 2.33 | 2.34 | 173.30K |
| Sep 30, 2026 | 2.35 | 2.41 | 2.35 | 2.38 | 118.20K |
| Sep 29, 2026 | 2.32 | 2.35 | 2.30 | 2.35 | 117.10K |
| Sep 28, 2026 | 2.34 | 2.35 | 2.32 | 2.33 | 94.10K |
| Sep 25, 2026 | 2.40 | 2.42 | 2.35 | 2.38 | 77.70K |
| Sep 24, 2026 | 2.34 | 2.38 | 2.33 | 2.37 | 111.40K |
| Sep 23, 2026 | 2.45 | 2.47 | 2.31 | 2.34 | 288.20K |
| Sep 22, 2026 | 2.46 | 2.50 | 2.41 | 2.49 | 231.00K |
About Compugen
Compugen (CGEN) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in HOLON, Israel. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 1119774.
CGEN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Anat Cohen-Dayag | Director | Jul 30, 2026 |
| Gilead Halevy | Director | Jul 30, 2026 |
| Michele Holcomb | Director | Mar 18, 2026 |
| Mathias Hukkelhoven | Director | Jul 30, 2026 |
| Savitzky Kinneret Livnat | Director | Jul 30, 2026 |
| Eran Ophir | President and CEO | Jul 30, 2026 |
| Eran Perry | Director | Jul 30, 2026 |
| Sanford S Zweifach | Director | Jul 30, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Pierre Ferre | Chief Operating Officer | Jul 30, 2026 |
| Russo Sharon Kredo | SVP, Research & Discovery | Jul 30, 2026 |
| Zurit Levine | SVP, Business Development | Jul 30, 2026 |
| Michelle Mahler | Chief Medical Officer | Jul 30, 2026 |
| Eran Ophir | President and CEO | Jul 30, 2026 |
| David Silberman | Chief Financial Officer | Jul 30, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 9, 2026 | Zurit Levine | Sale | 1,875 | $2.50 |
| Jul 9, 2026 | Zurit Levine | Sale | 1,875 | $2.50 |
| Jul 9, 2026 | Zurit Levine | Sale | 1,875 | $2.50 |
| Jul 9, 2026 | Zurit Levine | Sale | 1,875 | $2.50 |
| Apr 24, 2026 | Zurit Levine | Sale | 2,000 | $3.20 |
| Apr 24, 2026 | Zurit Levine | Sale | 2,000 | $3.20 |
| Apr 24, 2026 | Zurit Levine | Sale | 2,000 | $3.20 |
| Apr 24, 2026 | Zurit Levine | Sale | 2,000 | $3.20 |
| Apr 24, 2026 | Eran Ophir | Sale | 5,000 | $3.20 |
| Apr 24, 2026 | Eran Ophir | Sale | 5,000 | $3.20 |
| Apr 24, 2026 | Eran Ophir | Sale | 5,000 | $3.20 |
| Apr 24, 2026 | Eran Ophir | Sale | 5,000 | $3.20 |
| Apr 14, 2026 | Eran Ophir | Sale | 5,000 | $2.90 |
| Apr 14, 2026 | Eran Ophir | Sale | 5,000 | $2.90 |
| Apr 14, 2026 | Eran Ophir | Sale | 5,000 | $2.90 |
CGEN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
CGEN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Biogen (BIIB)Halozyme Therapeutics (HALO)Vaxcyte (PCVX)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on CGEN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.